TEC Edmonton helps researchers protect, develop and commercialize new technologies.

New Grants

NSERC I2I Phase I grant

TEC Edmonton has worked with Dr. James Harynuk in securing an NSERC I2I Phase I grant worth $125,000 to further the Harynuk group’s arson research and develop a fully fledged commercial prototype software package for arson investigation that will be subjected to ongoing testing and validation in the RCMP Forensics Laboratory.

Moreover, in order to prove that the core aspect of the software can be used for a variety of applications beyond arson investigations, the group will work towards demonstrating that their technology can improve offerings for automated identification of bacteria, which will open doors to many other opportunities.

Previously TEC Edmonton had been awarded with an NSERC I2I Market Assessment grant for this project, the outcome of which formed part of the successful Phase 1 application.

It was what you could realistically call a ringing endorsement of TEC Edmonton’s new TEC Health Accelerator, from Canada’s top health care investment banking firm, no less.

“Quite frankly, we first came to Edmonton secretly dreading the pitch we thought we’d hear from TEC,” said Brian Bloom, co-founder and president of Canada’s leading health care investment house, Bloom Burton & Co. Bloom was the keynote speaker at the launch of the TEC Edmonton TEC Health Accelerator, Nov. 27, 2014 in Edmonton.

Bloom is not one to pull his punches. “We regard many such (accelerator) projects as massive wastes of public dollars, as sinkholes of money. But TEC Edmonton’s TEC Health Accelerator is doing the right things. This is all about supporting winners, providing advisory services, mentoring, creating market awareness, networks and introductions so the cream can rise to the top.

“This is what accelerators should be doing, creating a faster path for the best companies to grow.”

Brian Bloom and Jolyon Burton have worked together for more than 12 years, and they formed Bloom Burton & Co. in 2008. Bloom Burton raises capital for health care companies, offers merger and acquisition advisory services, provides equity research with “analysts who aren’t afraid to call crap ‘crap’ and good stuff, ‘good stuff’ ”, directly invests in companies, and supports company creation and incubation through its consulting work.

Academic commercialization, bringing ideas and innovation to market that will ultimately improve health care delivery to patients, isn’t that hard to figure out, Bloom said.

Commercialization of health research should have higher priority within universities, he said. “Only a small sliver of academic curiosity-driven research has some commercial potential to start with.”

Industry and investors, he says, should be actively engaged with faculty researchers and inventors to determine market needs. Researchers and inventors, Bloom said, should be rewarded for their interest in commercialization. “Commercialization shouldn’t work against a researcher. It should count towards tenure.”

The $64,000 question in his business, said Bloom, is trying to judge the future, given the commercialization process takes years and years. “What the cholesterol market will look like in 10 years is a qualitative judgement. Trying to calculate value is tough!!”

In his talk, Bloom had fun dispelling myths about academic commercialization.

“They say ‘commercialization is difficult.’ Well it’s supposed to be difficult.

“ ‘Government should do more.’ Government already does a lot!

“ ‘The ‘valley of death’ is killing great ideas. Not it’s not! The ‘valley of death’ is a lovely place for ideas to shrivel up and die. Extraordinary ideas don’t die. They eventually find funding and support.

“As for the notion that there’s no money out there … the truth is there’s more money than there are good ideas worth investing in.”

He’s blunt. “Ninety percent of basic scientific research has no commercial potential. And most of the remaining 10% have the wrong plan to market or the wrong people. This can be fixed! This is where TEC Edmonton TEC Health Accelerator can contribute.”

His praise holds high value. “Bloom Burton will be working closely with the TEC Edmonton’s TEC Health Accelerator,” says Bloom. “We’re proud to be strategic partners.

“I would not attach our company’s name to any organization that we had any doubts about. We think the TEC Health Accelerator business model has got it right.”

Posted: Aug 12, 2019

Telebivudine to Abrogate Amyotrophic Lateral Sclerosis

Description Telbivudine Dr. Ted Allison and his team at the University of Alberta have discovered that telbivudine, a blood brain barrier-permeable thymidine analogue approved for treatment of Hepatitis B, is......

Posted: Jun 14, 2019

A Point-of-Care Diagnostic Tool to Replace Chest X-Ray for the Diagnosis of Childhood Pneumonia

Description University of Alberta researchers have discovered a novel set of biomarkers which can be used to diagnose pneumonia in children. The biomarkers include chitinase-3-like-1 (CHI3L1), lipocalin-2 (LCN-2), C-reactive protein......

Posted: Jun 14, 2019

Novel Cell Isolation Method for Bio-engineering Artificial Cartilage

Description University of Alberta researchers have developed a new method to isolate cells from knee joint (meniscus). The isolated cells are non-contractile in nature and do not form scar tissue.......

Posted: Jun 13, 2019

Novel Composite Monolith as a New Solid Phase Extraction Material for Environmental Analysis

Description University of Alberta researchers have developed a new material of a composite silica monolith nested in sponge (SiMNS) for solid phase extraction. The application of the new SiMNS material......

Posted: May 21, 2019

Self Assembling Peptide for Activating Human Mast Cells

Description Researchers at the University of Alberta have developed a novel biomaterial that can activate the body’s own innate immune response and accelerate the wound healing process. This technology may......

Posted: May 21, 2019

An Innocuous Structured Scaffold for Prion Disease Vaccines and Antigens

Description Researchers at the University of Alberta, led by Dr. Holger Wille, have developed a novel strategy for the creation of vaccines and specific antigens for prion protein diseases. Applying......

Posted: May 21, 2019

Spine Mounted Stereotactic System

Description Demonstration of stereotactic setup. An example of a commercially-available micromanipulator is shown. The setup can accommodate any micromanipulator design. Dr. Vivian Mushahwar and her team have developed an image-guided......

Posted: May 15, 2019

Method for the Production of Z-Olefins from 1,3-Dienes

Description Dr. Rylan Lundgren has developed a process for formate-mediated production of Z-olefins (also referred to as cis-alkenes) in the presence of a rhodium-based catalyst. The process is highly selective......

Posted: Apr 3, 2019

A Novel Method to Produce Pitched Kefir for Reducing Cholesterol

Description Researchers at the University of Alberta and TEAGASC have jointly developed a pitched-based method to produce kefir (a fermented milk beverage) that when consumed reduces blood cholesterol levels. The......

Posted: Nov 5, 2018

Novel F-18 Beta-Hydroxybutyric Acid Radiotracers for PET Imaging

Description Researchers at the University of Alberta have synthesized novel beta-hydroxybutyric acid radiotracers for PET imaging using a 3 step radiosynthetic process. The compounds are designed to serve as radiofluorinated......

Posted: Nov 5, 2018

A Novel Method for CryoPreservation of Cells in Monolayers

Description Researchers at the University of Alberta have developed a novel method to cryopreserve cells while adhered in a monolayer configuration. This method can preserve cells on a substrate and......

Posted: Oct 30, 2018

Train-Triggered Alert System for Conditioning and Warning Wildlife

Description Researchers at the University of Alberta have developed a novel, inexpensive, and compact system to alert wildlife to approaching trains, increasing the time available to avoid a collision. Rail-caused......